Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
IRAK4 TR-FRET assay from US Patent US11992481: "Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases"
Assay data:22 Active, 22 Activity ≤ 1 µM, 22 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
IRAK4 Kinase Activity Assay from US Patent US11958831: "Pyrazole compounds, pharmaceutical compositions thereof and use thereof"
Assay data:44 Active, 22 Activity ≤ 1 nM, 44 Activity ≤ 1 µM, 44 Tested
Biochemical Assay from US Patent US20240116922: "IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE"
Assay data:215 Active, 146 Activity ≤ 1 nM, 215 Activity ≤ 1 µM, 215 Tested
Methods for Evaluating TAK1 Modulators from US Patent US20240116893: "Compounds for Disease Treatment"
Assay data:8 Active, 8 Activity ≤ 1 µM, 8 Tested
IRAK4 Kinase Inhibitory Activity Assay from US Patent US20240132473: "SULFOXIMIDE SUBSTITUTED INDAZOLE IRAK4 KINASE INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF"
Assay data:40 Active, 35 Activity ≤ 1 nM, 40 Activity ≤ 1 µM, 40 Tested
Biological Assays against IRAK4 from US Patent US20240043405: "POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1"
Assay data:10 Active, 1 Activity ≤ 1 µM, 21 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
Human whole blood IRAK4 degradation flow assay from US Patent US11352350: "IRAK degraders and uses thereof"
Assay data:44 Active, 45 Activity ≤ 1 µM, 45 Tested
IRAK4 Invitrogen Lab (UK) kinase screen (BI)
Assay data:1 Tested
SummaryRelated BioAssays by Target
Inhibition of IRAK4 (unknown origin) at 10 uM by biochemical hotspot kinase assay
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of human GST-tagged IRAK4 incubated for 30 mins in presence of ATP by fluorescent polarization assay
Assay data:5 Active, 2 Activity ≤ 1 nM, 5 Activity ≤ 1 µM, 5 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of IRAK4 (unknown origin) at 1 uM relative to control
Assay data:3 Tested
Inhibition of IRAK4 (unknown origin) at 0.1 uM relative to control
Inhibition of human IRAK4 using biotinylated FGLARFSRFAGSSPSQSSMVARTQTVRGT peptide as substrate incubated for 1 hr in presence of ATP by ELISA assay
Assay data:22 Active, 22 Activity ≤ 1 µM, 23 Tested
Binding affinity to CRBN/IRAK4 in human PBMC cells assessed as inhibition of R848-stimulated IL-6 production incubated for 24 hrs by MSD analysis
Assay data:7 Active, 10 Activity ≤ 1 µM, 10 Tested
Binding affinity to CRBN/IRAK4 in human PBMC cells assessed as inhibition of R848-stimulated IL-6 production by measuring maximal efficacy incubated for 24 hrs by MSD analysis relative to control
Assay data:10 Tested
Binding affinity to CRBN/IRAK4 in human PBMC cells assessed as inhibition of LPS-stimulated IL-6 production incubated for 24 hrs by MSD analysis
Assay data:6 Active, 10 Activity ≤ 1 µM, 10 Tested
Binding affinity to CRBN/IRAK4 in human PBMC cells assessed as inhibition of LPS-stimulated IL-6 production by measuring maximal efficacy incubated for 24 hrs by MSD analysis relative to control
Binding affinity to human TNF-alpha assessed as binding constant (Koff) by SPR assay
Assay data:2 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on